Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BMS-791826 in Healthy Males
NCT03198013Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-791826 in Inflammatory Disorders (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events (AEs) up to 34 days and Incidence of serious adverse events (SAEs) up to 34 days. Started Nov 2008; status: completed.
02
Drugs
BMS-791826
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NCT03198013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198013.